Castle Bio Prices IPO at $16 per Share

Jul 25, 2019

|

NEW YORK — Skin cancer test developer Castle Biosciences said today that it has priced its planned initial public offering at $16 a share, the top end of the previously disclosed range.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Recent Headlines from
Precision Oncology News

UK-Led Team Pushes for Broader BRCA Screening Policies With Data on Ashkenazi Population
Premium
Repare Therapeutics Using CRISPR to Develop Cancer Treatments for Synthetic Lethal Targets
Premium
Squamous Cell Lung Cancer Subtypes Point to Potential Therapeutic Approaches
Premium
Novartis Launches Free BRAF Testing Program Hoping to Close Access Gaps, Maintain Market Lead
Premium
Study Documents Underuse of HBOC Testing in African American Breast Cancer Patients
Premium

The Scan

Gene Not Present

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

From the Brink?

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Employees Raise Testing Issues

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

PLOS Papers Explore HCC MicroRNAs, PCR-Based Schistosomiasis Diagnostics, More

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.

Featured White Papers

Analytical Validation of the Oncomine Pan-Cancer Cell-Free Assay

Multiplexed Infectious Disease Analysis

A High-Performance Solution Combining CleanPlex OncoZoom Cancer Hotspot Panel and SOPHiA AI for Rapid Characterization of Somatic Mutations

Benchmarking of the Microsart AMP Mycoplasma Kit with Products of Two Other Suppliers

Sep

18

Featured Webinar

Highly Sensitive Structural Variant Detection for Medical Genetics: A Comparison to the Standard of Care

This webinar will outline how a team at Radboud University Medical Center is assessing ultra-long read optical mapping on the Bionano Saphyr system to replace classical cytogenetics approaches in routine testing and for the discovery of novel structural variants with potential scientific, prognostic, or therapeutic value that are missed by standard approaches.

Sep

25

Featured Webinar

Biomarker Evaluation for CAR T-Cell Therapy: Impact on Drug Development

CAR T-cell therapy is an innovative form of immunotherapy that is finding increasing use for the management of blood cancers.

Oct

03

Featured Webinar

Streamlined and High-Precision Cancer Analysis Using an Automated NGS Workflow in the Reference Lab Setting

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct

08

Featured Webinar

Integration of Single Cell and Spatially Resolved Methods for Understanding Neurodegeneration in ALS

This webinar will discuss a study that used spatial transcriptomics to gain insight into the molecular mechanisms of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease.

Menu